Company Filing History:
Years Active: 2004-2009
Title: Innovative Contributions of Inventor Marc Chapdelaine
Introduction
Marc Chapdelaine is an accomplished inventor located in Wilmington, DE, USA. With an impressive portfolio of 13 patents, he has made significant strides in the field of pharmaceutical innovations. His work primarily focuses on compounds that target the nicotinic acetylcholine receptor, contributing to advancements in treating various medical conditions.
Latest Patents
Among his latest patents, Marc Chapdelaine has developed innovative ligands for the alpha 7 nicotinic acetylcholine receptor. These inventions include 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one and 5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands. The patent covers nicotinic acetylcholine receptor reactive compounds, described by a specific formula, where D represents O, E represents CH2, NH, O or S, and n can be 1 or 2. He also addresses the stereoisomers, enantiomers, in vivo-hydrolysable precursors, and pharmaceutically acceptable salts of such compounds. The methodologies for their use in treating diseases, including anxiety disorders, cognitive disorders, and mood disorders, are also part of his patented work.
Career Highlights
Marc Chapdelaine is currently affiliated with AstraZeneca AB, a renowned global biopharmaceutical company. His innovative contributions have helped in the development of novel therapeutic approaches, showcasing his expertise and dedication to improving health outcomes.
Collaborations
Throughout his career, Marc has had the opportunity to collaborate with esteemed colleagues such as John McCauley and Edward Pierson. These collaborations have undoubtedly enriched his research, leading to significant breakthroughs in the pharmaceutical field.
Conclusion
In conclusion, Marc Chapdelaine stands out as a pivotal inventor in the realm of pharmaceutical innovations. His numerous patents demonstrate his commitment to advancing medical science, particularly in developing treatments for cognitive and mood disorders. As he continues to work within AstraZeneca AB and beyond, his contributions will likely play a significant role in shaping future therapeutic strategies.